Seres Therapeutics, Inc. (NASDAQ:MCRB) microbiome therapeutics platform provider will be discussing 3Q20 financial results with the investment community.on 9th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.serestherapeutics.com
Earnings Expectation
Seres Therapeutics, Inc. is set to announce third quarter earning results on Monday 9th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, MCRB to report 3Q20 loss of $ 0.25 per share. For the full year, analysts anticipate top line of $ 29.03 million, while looking forward to loss of $ 0.96 per share bottom line.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The companys advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy.
